Recent 8-K filings for SRTA

• June 3, 2026, 4:25 PM ET other materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×3

  Strata Critical Medical stockholders elect directors Heyburn and Lauck, ratify Deloitte, approve say-on-pay

  William A. Heyburn re-elected with 46,050,902 for, 505,421 withhold, 12,687,496 broker non-votes.

• May 6, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Strata Critical Medical Q1 revenue up 87% to $67.4M; net income $2.4M vs prior loss

  Revenue $67.4M (up 87.4% YoY); net income from cont. ops $2.4M vs loss of $1.6M YoY.

• March 3, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Strata Critical Medical Q4 revenue up 83.5% YoY to $66.8M; raises FY2026 guidance

  Q4 2025 revenue $66.8M (+83.5% YoY); logistics revenue up 35.3% to $49.2M.

• February 5, 2026, 6:59 PM ET debt materiality 0.65 positive item 1.01item 7.01item 9.01 ◈ Material Agreements

  Strata Critical Medical secures $30M ABL credit facility from JPMorgan for acquisitions

  Entered Credit Agreement for up to $30M revolving ABL facility, expandable to $50M subject to conditions.

• December 3, 2025, 6:59 PM ET leadership materiality 0.35 neutral item 5.02item 7.01item 9.01

  Strata Critical Medical appoints Will Cook to board of directors

  William L. Cook III appointed as Class I director effective Dec 2, 2025; board expanded from eight to nine directors.

• December 2, 2025, 6:59 PM ET M&A materiality 0.80 neutral item 9.01item 2.01 ◈ M&A Transactions

  Strata Critical Medical amends 8-K to include Keystone financials; acquisition closed

  Acquisition of Keystone Perfusion Services closed Sep 16, 2025; all equity interests acquired.

• November 10, 2025, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Strata Critical Medical Q3 revenue up 36.7% to $49.3M; net loss widens to $9.7M

  Revenue $49.3M, up 36.7% YoY; organic growth 29.0% excluding Keystone acquisition.

• September 16, 2025, 7:59 PM ET M&A materiality 0.85 positive item 1.01item 2.01item 9.01item 3.02item 7.01 ◈ M&A Transactions

  Strata completes $124M acquisition of Keystone Perfusion, updates 2025 guidance

  Total upfront consideration of $124M (88% cash, 12% stock) at ~9x Keystone's estimated 2025 Adjusted EBITDA of ~$13M.

• September 12, 2025, 7:59 PM ET other materiality 0.15 neutral item 5.07

  Strata Critical Medical Board sets annual say-on-pay votes until 2031

  Stockholders voted for annual say-on-pay frequency at May 6, 2025 meeting.

• August 29, 2025, 7:59 PM ET leadership materiality 0.60 neutral item 5.02item 9.01

  Strata Critical Medical appoints Co-CEOs Tomkiel and Heyburn, approves $550K salary and PSUs

  Melissa Tomkiel and William Heyburn became Co-CEOs effective Aug 1, 2025, retaining General Counsel and CFO roles respectively.

• August 29, 2025, 7:59 PM ET M&A materiality 0.90 positive item 1.01item 2.01item 5.02item 5.03item 7.01item 8.01item 9.01 ◈ Governance Changes ×2◈ M&A Transactions

  Strata Critical Medical closes Passenger sale to Joby for ~$76M in stock; shifts to medical transport

  Completed sale of Passenger business to Joby Aero on Aug 29; received ~$76M in 5.3M Joby shares, plus up to $35M earnout and $10M holdbacks.

• August 5, 2025, 7:59 PM ET other material materiality 0.85 positive item 2.02item 9.01

  Blade Air Mobility Q2 net loss narrows to $3.7M; sells Passenger division to Joby for up to $125M

  Q2 net loss improved $7.6M YoY to $(3.7)M; Adjusted EBITDA $3.2M vs $0.96M YoY.

• August 4, 2025, 7:59 PM ET M&A materiality 0.75 positive item 1.01item 5.02item 7.01item 9.01

  Blade sells passenger division to Joby for up to $125M; to rebrand as Strata

  Up to $125M consideration (cash or Joby stock): $90M at close plus up to $35M earnout tied to performance and retention.

• May 12, 2025, 7:59 PM ET earnings materiality 0.55 positive item 2.02item 9.01

  Blade Q1 revenue $54.3M (+5.4% YoY); net loss improves to $(3.5)M; reaffirms FY2025 positive Adj. EBITDA

  Revenue $54.3M (+5.4% YoY); excluding exited Canada, up 10.9%.

• May 8, 2025, 7:59 PM ET other material materiality 0.15 neutral item 5.07

  Blade Air Mobility annual meeting elects directors, ratifies auditor, approves say-on-pay

  Three Class I directors elected: John Borthwick (39.3M for, 6.4M withhold), Reginald Love (28.7M for, 17.0M withhold), Edward Philip (43.5M for, 2.2M withhold).

• March 13, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Blade Air Mobility Q4 revenue up 14.5% to $54.4M; Net loss narrows 71% YoY

  Q4 revenue $54.4M (+14.5% YoY); net loss improved 71% to $(9.8)M from $(33.9)M.

• November 12, 2024, 6:59 PM ET earnings materiality 0.55 neutral item 2.02item 9.01

  Blade Air Mobility Q3 revenue $74.9M (+4.8%); net loss $(2.0)M; Adj EBITDA $4.2M

  Revenue $74.9M, up 4.8% YoY; gross margin improved 520 bps to 19.3%.

• August 7, 2024, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01

  Blade Air Mobility Q2 net loss narrows to $11.3M; first public Q2 with positive Adj. EBITDA $1.0M

  Net loss of $11.3M improved $0.9M YoY; revenue $67.9M up 11.4% YoY.

• May 7, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Blade Q1 net loss narrows to $4.2M; Medical revenue record $36M, up 34.6% YoY

  Total Q1 revenue of $51.5M, up 13.8% YoY; Medical segment revenue hit a record $36.0M.

• May 7, 2024, 7:59 PM ET other material materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×2

  Blade Air Mobility stockholders elect directors and ratify auditor at 2024 annual meeting

  Susan Lyne elected as Class III director with 28,648,946 for, 8,168,466 withheld; Robert Wiesenthal with 30,585,817 for, 6,231,595 withheld.

• March 22, 2024, 7:59 PM ET other material materiality 0.55 neutral item 4.01item 9.01 ◈ Auditor Changes ×2

  Blade Air Mobility dismisses Marcum, appoints Deloitte as auditor for FY2024

  Audit committee dismissed Marcum LLP on March 19, 2024; no disagreements on accounting or auditing matters.

• March 20, 2024, 7:59 PM ET other material materiality 0.60 positive item 8.01item 9.01

  Blade Air Mobility announces up to $20M share repurchase program; expects FY2024 adj. EBITDA profit

  Board authorized repurchase of up to $20M of Class A common stock; program effective through March 31, 2025.

• March 12, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Blade Q4 revenue up 24.5% to $47.5M; guides for 2024 Adj. EBITDA profitability

  Q4 revenue $47.5M (+24.5% YoY); full year revenue $225.2M (+54.1%).

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.65 · Most common event earnings

13 positive 0 negative 10 neutral

source · SRTA on sec.gov